Cholera/enterotoxigenic Escherichia coli vaccine - Celldex Therapeutics

Drug Profile

Cholera/enterotoxigenic Escherichia coli vaccine - Celldex Therapeutics

Alternative Names: Cholera/ETEC vaccine; Combined ETEC-cholera vaccine [Peru-15-pCTB (Cholera toxin B-subunit)] - Celldex/NIAID; Combined live, attenuated, enterotoxigenic Escherichia coli (ETEC)-cholera Vaccine (Peru-15 pCTB) - Celldex Therapeutics/NIAID; ETEC/cholera vaccine; Peru-15 pCTB; Traveller's diarrhoea vaccine - Celldex Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celldex Therapeutics Inc
  • Developer Celldex Therapeutics Inc; National Institute of Allergy and Infectious Diseases
  • Class Cholera vaccines; Escherichia coli vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cholera; Escherichia coli infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cholera(Prevention, In volunteers) in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Escherichia-coli-infections(Prevention, In volunteers) in USA (PO)
  • 03 Feb 2011 NIAID completes a Phase-I clinical trial in the prevention of Escherichia coli infections and cholera (in volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top